A drug commonly used to treat rheumatoid arthritis can suppress the progression of type 1 diabetes in recently diagnosed patients, scientists have said.
In a world-first clinical trial, researchers in Australia have found that baricitinib, which is available in the UK under the brand name Olumiant, can preserve the body’s own insulin production, reducing the amount of insulin needed to treat the condition.
